

Pharmaceutical Benefits Advisory Committee

Email: PBAC@health.gov.au

Address all mail to:
PBAC Secretariat
GPO Box 9848
Canberra ACT 2601

DELISTING OF PHARMACEUTICAL BENEFIT ITEMS EFFECTIVE 01 SEPTEMBER 2024

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act 1953*, with effect from the above date.

Item

PBAC Advice

Fosinopril with
hydrochlorothiazide

The sponsor requested the delisting of Fosetic[®] 20/12.5 (fosinopril with hydrochlorothiazide) from the Pharmaceutical Benefits Scheme (PBS).

The Pharmaceutical Benefits Advisory Committee (PBAC) noted the low number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need.

Vanessa McMahon
Director, PBAC Assessment Section
Office of Health Technology Assessment
Technology Assessment and Access Division
21 August 2024